Abbott Laboratories 10-Q Summary: Period Ended September 30, 2002
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, for the period ended September 30, 2002. The company operates in five reportable segments: Pharmaceutical Products, Diagnostic Products, Hospital Products, Ross Products, and International. As of September 30, 2002, there were 1,562,540,625 common shares outstanding.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 |
|---|---|---|
| Net Sales | $4,341.2 million | $12,845.4 million |
| Operating Earnings | $913.4 million | $2,641.3 million |
| Net Earnings | $720.1 million | $2,166.6 million |
| Diluted EPS | $0.46 | $1.38 |
| Gross Profit Margin | 52.4% | 52.3% |
| Net Cash from Operating Activities | N/A | $2,983.4 million |
| Working Capital | $1.767 billion | N/A |
| Cash and Cash Equivalents | $742.6 million | N/A |
| Total Debt (Short-term + Long-term) | $6.937 billion | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3.8% in the third quarter and 8.5% for the first nine months compared to 2001. Excluding foreign exchange, sales increased 3.0% (Q3) and 9.3% (9 months).
- Profitability: Net earnings rose 14.0% in Q3 and 131.3% for the nine-month period. The significant year-over-year increase in the nine-month period is largely due to the absence of a $1.187 billion charge for acquired in-process research and development (IPR&D) related to the BASF acquisition in 2001.
- One-Time Charges: In 2002, the company recorded a $129 million pre-tax charge related to a U.S. FDA consent decree regarding diagnostics manufacturing operations (recorded in Q2). In Q3 2002, there were no IPR&D charges, compared to $1.187 billion in the same period in 2001.
- Segment Performance: International sales grew 15.5% (9 months) and Pharmaceutical sales grew 13.3% (9 months), driven by the BASF acquisition. Ross Products sales declined slightly (1.1% for 9 months).
Guidance, Outlook, Risks, and Unusual Items
- Restructuring Plans (Subsequent Event): In October 2002, Abbott announced restructuring plans affecting approximately 2,000 employees. The company expects to record an after-tax charge of $100 million to $125 million in Q4 2002, with expected annual after-tax savings of $80 million to $100 million.
- FDA Consent Decree: The FDA found Abbott's Lake County diagnostics operations non-conforming with Quality System Regulations in May 2002. While a $129 million charge was taken in Q2, ongoing earnings per share are expected to be negatively impacted by approximately 9 cents in 2002 and 18 cents in 2003. Further costs may arise if re-inspection fails.
- Legal Proceedings:
- Antitrust: Various suits allege price-fixing and discrimination in prescription pharmaceutical pricing. Abbott denies allegations.
- Enteral Nutritional Investigation: The U.S. Attorney's Office is conducting a civil and criminal investigation of the enteral nutritional business (Ross division). An adverse outcome could materially affect cash flows and results of operations.
- TAP Joint Venture: Abbott recorded a loss of $171.6 million in Q3 2002 from its TAP Pharmaceutical Products Inc. joint venture, related to the DOJ investigation of Lupron marketing.
- Patent Litigation: A jury awarded $5 million in damages to a third party regarding Abbott's Gengraf product; Abbott intends to appeal.
- Co-Promotion Dispute: Abbott has recorded $73 million in receivables from a co-promotion agreement. The partner disputes the calculation, and the parties are seeking arbitration. Abbott expects to record an additional $25 million in revenue in Q4 2002.
Investor Verification Checklist
- FDA Compliance Status: Verify the outcome of the upcoming re-inspection of the Lake County diagnostics facility and potential additional costs beyond the $129 million charge.
- Restructuring Execution: Monitor the Q4 2002 financials for the anticipated $100-$125 million after-tax restructuring charge and the timeline for realizing the projected $80-$100 million in annual savings.
- Legal Exposure: Track the status of the U.S. Attorney's investigation into the Ross division and the arbitration regarding the $73 million co-promotion receivable.
- TAP Joint Venture Impact: Assess the ongoing financial impact of the TAP joint venture losses and the resolution of the Lupron-related DOJ settlement.
- Goodwill and Intangibles: Review the annual goodwill impairment assessment results (completed in Q3 2002 with no charges) and the amortization schedule for newly acquired intangible assets.